Targeting prEssure-Muscle-index to Avoid Ventilatory Over-Assistance During Pressure Support Ventilation

NCT ID: NCT06921655

Last Updated: 2025-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-01

Study Completion Date

2027-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The TEMA study (Targeting prEssure-Muscle-index to avoid ventilatory over-Assistance during pressure support ventilation) is a prospective, interventional crossover trial investigating the relationship between pressure support (PS) and tidal volume (Vt) in ICU patients with acute hypoxemic respiratory failure (AHRF) receiving pressure support ventilation (PSV). The study aims to assess whether the Pressure-Muscle Index (PMI)-a marker derived from the difference between plateau and peak inspiratory pressure-can help identify the optimal level of ventilatory assistance, preventing over-assistance and its associated complications such as diaphragm atrophy and patient self-inflicted lung injury (P-SILI). By exploring the sigmoidal relationship between PS and Vt, the study seeks to define a physiological threshold (PMI=0) that may serve as a personalized target for PSV titration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TEMA study is a prospective, interventional crossover trial designed to explore the physiological relationship between levels of pressure support (PS) and tidal volume (Vt) in mechanically ventilated ICU patients diagnosed with acute hypoxemic respiratory failure (AHRF). The goal is to identify a pressure support threshold beyond which over-assistance occurs, leading to excessive tidal volumes and suppression of respiratory muscle activity.

The central hypothesis is that the PS-Vt curve follows a sigmoidal pattern: an initial plateau phase with stable Vt is followed by a steep, compliance-driven increase in Vt at higher PS levels. The Pressure-Muscle Index (PMI), calculated as the difference between plateau pressure (Pplat) and peak airway pressure (Ppeak) during an inspiratory occlusion, is used to define this inflection point (PMI=0), which marks the transition from physiologically appropriate to excessive assistance.

Study Design: The study is conducted at the ICU of Santa Chiara Hospital (Trento, Italy) and includes seven levels of pressure support modulation-three above and three below the identified PMI=0 point. At each level, key physiological variables such as Vt, respiratory rate (RR), minute ventilation, PMI, and patient-ventilator asynchrony index are recorded.

A second evaluation between days 4-6 post-enrollment is planned for patients who remain intubated, to assess whether the PS-Vt relationship evolves over time, reflecting changes in respiratory drive and mechanics during the ICU course.

Technical Aspects:

Measurements include respiratory system compliance, work of breathing (WOB), inspiratory effort, and occlusion-based indices.

PS levels are applied in randomized order to minimize bias. Clinical PSV settings are reinstated between steps to avoid carryover effects and ensure patient safety.

Analytical Approach: The primary outcome is to characterize the PS-Vt relationship and validate the use of PMI as a physiological marker of the optimal support threshold. Nonlinear regression models, including sigmoidal curve fitting, will be used to identify inflection points (c parameters) in the PS-Vt curve. A Monte Carlo simulation informed the sample size, targeting 36 patients to account for potential dropouts, ensuring \>90% power to detect a meaningful breakpoint.

Multivariable models will adjust for potential confounders such as PaCO₂, sedation depth, BMI, and baseline compliance.

Expected Impact: If successful, the TEMA study will provide a new physiologically grounded framework for tailoring pressure support in assisted ventilation. By validating PMI as a real-time bedside tool, the study may support a more personalized approach to weaning and ventilation management, potentially improving outcomes such as duration of ventilation, weaning success, and ICU stay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Hypoxemic Respiratory Failure Mechanical Ventilation Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized Cross-over
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pressure Support PMI=0

The PS level at which PMI is zeroed, meaning the patient's inspiratory effort contributes minimally to tidal volume

Group Type EXPERIMENTAL

Variation of Pressure Support Levels

Intervention Type PROCEDURE

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Pressure Support +2

Above PSPMI=0: +2 cmH₂O above PSPMI=0 (over-assistance zone).

Group Type EXPERIMENTAL

Variation of Pressure Support Levels

Intervention Type PROCEDURE

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Pressure Support +4

Above PSPMI=0: +4 cmH₂O above PSPMI=0 (over-assistance zone).

Group Type EXPERIMENTAL

Variation of Pressure Support Levels

Intervention Type PROCEDURE

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Pressure Support +6

Above PSPMI=0: +6 cmH₂O above PSPMI=0 (over-assistance zone).

Group Type EXPERIMENTAL

Variation of Pressure Support Levels

Intervention Type PROCEDURE

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Pressure Support -2

Below PSPMI=0: -2 cmH₂O below PSPMI=0 (under-assistance zone).

Group Type EXPERIMENTAL

Variation of Pressure Support Levels

Intervention Type PROCEDURE

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Pressure Support -4

\- Below PSPMI=0: -4 cmH₂O below PSPMI=0 (under-assistance zone).

Group Type EXPERIMENTAL

Variation of Pressure Support Levels

Intervention Type PROCEDURE

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Pressure Support -6

\- Below PSPMI=0: -6 cmH₂O below PSPMI=0 (under-assistance zone).

Group Type EXPERIMENTAL

Variation of Pressure Support Levels

Intervention Type PROCEDURE

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Variation of Pressure Support Levels

Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥ 18 years
2. Mechanically ventilated in the ICU
3. Diagnosis of Acute Hypoxemic Respiratory Failure (AHRF)
4. Normocapnia or non-severe hypercapnia
5. Receiving Pressure Support Ventilation (PSV) for at least 24-72 hours
6. Presence of an arterial line for blood gas sampling

Exclusion Criteria

1. Age \< 18 years
2. Known neurological or neuromuscular disorders affecting diaphragm function
3. Chronic Obstructive Pulmonary Disease (COPD) or hypercapnic respiratory failure
4. Psychomotor agitation or inadequate sedation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre for Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Centre for Medical Sciences

Professor Giacomo Bellani

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Medical Sciences

Trento, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Giacomo Bellani, MD, PhD

Role: primary

Eleonora Balzani, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TEMA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.